Asset Details
Do you wish to reserve the book?
Triazole‐Derived Ruthenium(II) Complexes as Novel Candidates for Cancer Therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Triazole‐Derived Ruthenium(II) Complexes as Novel Candidates for Cancer Therapy
Do you wish to request the book?
Triazole‐Derived Ruthenium(II) Complexes as Novel Candidates for Cancer Therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Triazole‐Derived Ruthenium(II) Complexes as Novel Candidates for Cancer Therapy
2025
Overview
The first examples of Ru(II) η6‐arene (benzene and p‐cymene) complexes containing a bidentate triazolylidene‐triazolide ligand have been prepared and fully characterized. Their antiproliferative effect has been investigated against tumour cells A2780 (ovarian carcinoma), HCT116 (colorectal carcinoma), and HCT116dox (colorectal carcinoma resistant to doxorubicin), and in human dermal fibroblasts. The Ru complex bearing the p‐cymene arene group exhibited a stronger antiproliferative effect across all tested cell lines, while the benzene‐containing complex displayed higher selectivity toward tumor cells. Both complexes induced apoptosis, likely through ROS production (in the benzene complex), and inhibited tumorigenic processes, including cell migration and angiogenesis. In zebrafish models, they showed strong selectivity for cancer cells with minimal toxicity to healthy cells, effectively reducing the proliferation of HCT116 colorectal cancer cells. This study provides the first in vivo evidence of the anticancer potential of Ru triazolylidenes in zebrafish models. The anticancer potential of Ru(II) complexes with bidentate triazolylidene‐triazolide ligands has been demonstrated against A2780 (ovarian carcinoma), and HCT116 (colorectal carcinoma) tumor cell lines. The work provides an in‐depth evaluation of these complexes, examining their in vitro antiproliferative activity, mechanisms of inducing cell death, cell migration, anti‐angiogenic effects, and therapeutic performance in vivo zebrafish xenograft models.
Subject
/ Antineoplastic Agents - chemical synthesis
/ Antineoplastic Agents - chemistry
/ Antineoplastic Agents - pharmacology
/ Cell Movement - drug effects
/ Cell Proliferation - drug effects
/ Coordination Complexes - chemical synthesis
/ Coordination Complexes - chemistry
/ Coordination Complexes - pharmacology
/ Drug Screening Assays, Antitumor
/ Humans
